|Bid||30.51 x 100|
|Ask||31.21 x 100|
|Day's Range||29.45 - 31.70|
|52 Week Range||20.50 - 39.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.25|
An East Bay biotech company, attempting to find next-generation ways to stimulate the immune system to fight cancer, raised $120 million in an upsized initial public offering. The IPO from Hayward's Arcus Biosciences Inc. (RCUS) priced at $15 — at the high end of the company's range — as it increased the number of shares available from 7.1 million to 8 million. It is the third IPO among Bay Area life sciences companies this year.
A pair of IPOs from Bay Area companies are expected at the end of the week from Zscaler Inc. and Arcus Biosciences Inc. The one from San Jose-based cloud security company Zscaler is expected Friday and would be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) went public. The offering from Arcus Biosciences is the third from a Bay Area biotech, following two at the end of January from Redwood City companies ARMO Biosciences Inc. (ARMO) and Menlo Therapeutics Inc. (MNLO).
The targets have been raised again for what's expected to be the first Bay Area tech IPO in four months. San Jose-based Zscaler Inc. increased the amount of stock for sale and the price targets on its offer, boosting how much it could raise to about $207 million, up 50 percent. It was valued by private investors at a little over $1 billion when it raised its last venture round in the summer of 2015.
Friday's offering from San Jose-based cloud security company Zscaler is set to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix went public.
Cloud security unicorn Zscaler Inc. set a price range for its upcoming IPO that would raise up to about $138 million and boost its valuation by about 40 percent. The San Jose company would be valued at around $1.4 billion at the high end of its proposed price range of between $10 and $12 a share. It's in line to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) raised $120 million.
Cloud security unicorn Zscaler Inc. is the most likely candidate to end the Bay Area's latest tech IPO drought. There were only six tech IPOs from the region last year that raised more than $100 million. Uncertainties over the massive tax overhaul and disappointing Wall Street debuts from technology unicorns Snap and Blue Apron were blamed for keeping Valley IPOs down last year, along with IPO-sized late stage funding rounds from investors like Softbank.
REDWOOD CITY, Calif., Feb. 20, 2018-- Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying ...
CFO software developer Adaptive Insights Inc. is reportedly lining up an IPO. The Palo Alto-based business has hired Morgan Stanley to lead the offering, Reuters said it was told by unnamed sources. Adaptive Insights was launched by Robert Hull in 2003 to build a cloud-based software platform that chief financial officers can use for budgeting, forecasting, reporting, consolidation, dashboards and analytics aimed at finance, sales and other business enterprises.
The potential for mergers and acquisitions in biopharma—driven by the new business-friendly tax package—is fueling investor enthusiasm for biotech IPOs.
REDWOOD CITY, Calif., Jan. 29, 2018-- Menlo Therapeutics Inc. today announced the closing of the Company’ s initial public offering of 8,050,000 shares of common stock at a public offering price of $17.00 ...
After a strong run of IPOs in 2017, venture-backed ARMO BioSciences Inc., resTORbio Inc., and Solid Biosciences were the latest to join a parade of solid offerings.
Drug company investors buoyed by a series of multibillion-dollar mergers pushed Menlo Therapeutics Inc.'s stock up 69 percent higher than the company's IPO price on Thursday. The Redwood City company (NASDAQ: ...
Menlo Therapeutics Inc. priced its initial public offering late Wednesday at $17 a share, the high end of its $16 to $17 range, according to Nasdaq. The company sold 7 million shares to raise $119 million. ...
REDWOOD CITY, Calif., Jan. 24, 2018-- Menlo Therapeutics Inc. today announced the pricing of the Company’ s initial public offering of 7,000,000 shares of common stock at a public offering price of $17.00 ...
Menlo Therapeutics Inc. raised $119 million in its initial public offering, after pricing its shares at the upper end of its estimated range.
Biotech Menlo Therapeutics Inc. has increased the size of its planned initial public offering and raised the price range, according to a regulatory filing. The company is now planning to offer 6.5 million ...